News

Following the launch of its PanExcea performance excipient, Mallinckrodt Baker is teaming with Rubicon Research to expand its performance excipient platform. The two companies will develop and launch

The study, which was conducted in normal adult volunteers, showed that LT-NS001 was well-tolerated by the recipients. Moreover, when the subjects in the study were dosed twice daily

The study will be conducted at four clinical trial sites for a period of nine to 12 months and include up to 40 subjects. The drug will be

This study was a multi-centre, randomized, double blind, evaluation of the efficacy and safety of Uracyst versus placebo in patients with interstitial cystitis or painful bladder syndrome. The

The company also received a notice from the US Patent and Trademark Office that it intends to grant a patent with claims covering certain methods for treating multidrug-resistant

According to the company, AurPROFILER enables researchers to rapidly evaluate target, cell and drug profiles using bio-assays derived from the activity data found in Aureus Pharma’s AurSCOPE target

Dr Stromatt replaces Daniel Burge who will be resigning his position with the company for personal reasons in late August 2008. Most recently, Dr Stromatt was executive vice

The Edema4 trial, conducted under a special protocol assessment granted by the FDA, achieved statistically significant improvements in the intent-to-treat population in primary and secondary endpoints. DX-88 was

Bupropion hydrochloride extended-release tablets (XL), available in 300mg strength, are the generic equivalent of Wellbutrin XL for the treatment of major depressive disorder. Douglas Boothe, CEO of Actavis,